- Training
- December 2026
- 2 Days
Global
€1605EUR$1,798USD£1,299GBP
€1852EUR$2,075USD£1,499GBP
- Training
- November 2026
- 5 Days
Global
€1976EUR$2,213USD£1,599GBP
€2347EUR$2,629USD£1,899GBP
- Newsletter
- October 2026
Global
€2767EUR$2,995USD£2,318GBP
- Report
- October 2025
- 90 Pages
Global
From €4158EUR$4,500USD£3,482GBP
- Report
- September 2026
- 291 Pages
Europe
From €4434EUR$4,799USD£3,714GBP
- Report
- September 2026
- 293 Pages
North America
From €4434EUR$4,799USD£3,714GBP
- Report
- April 2026
- 150 Pages
United States
From €5497EUR$5,950USD£4,604GBP
- Report
- July 2026
- 80 Pages
North America
From €4389EUR$4,750USD£3,676GBP
- Report
- February 2026
- 150 Pages
United States
From €4481EUR$4,850USD£3,753GBP
- Report
- April 2026
North America
From €3188EUR$3,450USD£2,670GBP
- Report
- April 2026
Asia Pacific
From €3188EUR$3,450USD£2,670GBP
- Report
- March 2026
Africa, Middle East
From €3188EUR$3,450USD£2,670GBP
- Report
- October 2025
- 85 Pages
Middle East
From €4158EUR$4,500USD£3,482GBP
- Report
- June 2021
- 123 Pages
Global
From €1198EUR$1,297USD£1,004GBP
- Report
- July 2020
- 269 Pages
Global
From €3231EUR$3,497USD£2,706GBP
- Report
- August 2019
- 264 Pages
Global
From €3691EUR$3,995USD£3,092GBP
- Report
- September 2026
China
From €4434EUR$4,799USD£3,714GBP
- Report
- February 2023
- 336 Pages
Global
From €4434EUR$4,799USD£3,714GBP
- Report
- January 2025
- 252 Pages
China
From €4434EUR$4,799USD£3,714GBP
- Report
- August 2024
- 381 Pages
Global
From €4434EUR$4,799USD£3,714GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more